| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
49,335 |
42,012 |
$3.38M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
49,814 |
44,978 |
$3.13M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
24,169 |
17,944 |
$1.35M |
| 70450 |
Computed tomography, head or brain; without contrast material |
11,617 |
9,459 |
$1.18M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
5,453 |
4,750 |
$801K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
39,659 |
29,246 |
$788K |
| 80053 |
Comprehensive metabolic panel |
38,768 |
29,521 |
$762K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
5,739 |
4,836 |
$680K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
8,141 |
7,451 |
$637K |
| G0378 |
Hospital observation service, per hour |
25,293 |
12,276 |
$436K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
3,795 |
3,356 |
$390K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
3,160 |
2,863 |
$291K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
2,117 |
1,827 |
$273K |
| A9270 |
Non-covered item or service |
34,532 |
4,908 |
$266K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
4,146 |
3,701 |
$194K |
| 71046 |
Radiologic examination, chest; 2 views |
5,383 |
4,875 |
$143K |
| G0257 |
Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility |
683 |
148 |
$138K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,572 |
1,435 |
$131K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
2,801 |
741 |
$126K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
2,492 |
2,114 |
$111K |
| 87070 |
|
6,704 |
6,200 |
$93K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
7,690 |
6,039 |
$82K |
| 85027 |
|
83,400 |
58,163 |
$81K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
2,870 |
1,923 |
$77K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,093 |
998 |
$77K |
| 87275 |
|
11,546 |
10,688 |
$71K |
| 73564 |
|
2,188 |
1,897 |
$70K |
| 71045 |
Radiologic examination, chest; single view |
31,642 |
26,009 |
$70K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
9,407 |
7,742 |
$69K |
| 93976 |
|
2,610 |
2,279 |
$67K |
| 73610 |
|
1,681 |
1,498 |
$65K |
| 81001 |
|
25,748 |
22,239 |
$64K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
17,240 |
15,441 |
$62K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
4,704 |
3,330 |
$60K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
1,205 |
983 |
$60K |
| 73130 |
|
1,527 |
1,358 |
$58K |
| 72131 |
|
898 |
737 |
$53K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
867 |
801 |
$53K |
| 81025 |
|
11,405 |
10,347 |
$52K |
| 80076 |
|
9,602 |
8,642 |
$49K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
29,320 |
22,209 |
$48K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
9,608 |
8,275 |
$47K |
| 73630 |
|
2,038 |
1,840 |
$47K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,382 |
1,194 |
$44K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
4,209 |
3,336 |
$43K |
| 73110 |
|
1,137 |
1,030 |
$42K |
| 73030 |
|
1,688 |
1,408 |
$42K |
| 71250 |
|
857 |
671 |
$38K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
966 |
834 |
$38K |
| 84703 |
|
21,042 |
18,411 |
$35K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
34,731 |
28,791 |
$35K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
5,159 |
3,824 |
$35K |
| 10060 |
|
318 |
297 |
$33K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
32,314 |
24,022 |
$32K |
| 85610 |
|
14,421 |
11,112 |
$29K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
1,955 |
1,761 |
$29K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
3,065 |
2,235 |
$27K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
2,812 |
1,965 |
$26K |
| 85730 |
|
12,764 |
9,962 |
$26K |
| 74018 |
|
534 |
485 |
$26K |
| 72100 |
|
1,209 |
1,057 |
$25K |
| 84484 |
|
26,654 |
16,811 |
$25K |
| J1644 |
Injection, heparin sodium, per 1000 units |
4,780 |
2,169 |
$24K |
| 00731 |
|
290 |
260 |
$24K |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
75 |
15 |
$24K |
| 12001 |
|
363 |
335 |
$23K |
| 81003 |
|
8,372 |
7,301 |
$23K |
| 73080 |
|
607 |
534 |
$22K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
1,498 |
986 |
$21K |
| 12011 |
|
305 |
272 |
$20K |
| 82077 |
|
4,239 |
3,414 |
$20K |
| C1769 |
Guide wire |
692 |
512 |
$20K |
| 86850 |
|
3,846 |
3,163 |
$20K |
| J2704 |
Injection, propofol, 10 mg |
2,022 |
1,558 |
$19K |
| 97163 |
|
1,274 |
983 |
$19K |
| S0028 |
Injection, famotidine, 20 mg |
2,402 |
1,921 |
$19K |
| 93971 |
|
1,436 |
1,244 |
$17K |
| J7050 |
Infusion, normal saline solution, 250 cc |
6,074 |
4,244 |
$16K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
1,928 |
1,656 |
$15K |
| 84702 |
|
5,001 |
4,113 |
$14K |
| 82550 |
|
11,334 |
8,017 |
$13K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
12,759 |
9,483 |
$13K |
| 80047 |
|
534 |
386 |
$13K |
| 83690 |
|
19,754 |
16,570 |
$13K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
112 |
103 |
$13K |
| 87088 |
|
4,583 |
3,913 |
$13K |
| 93970 |
|
347 |
289 |
$13K |
| 82553 |
|
4,086 |
2,392 |
$12K |
| 70486 |
|
917 |
778 |
$12K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,486 |
1,747 |
$12K |
| 70496 |
|
78 |
66 |
$12K |
| 76830 |
Ultrasound, transvaginal |
855 |
783 |
$12K |
| 87077 |
|
2,476 |
2,038 |
$11K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
115 |
106 |
$11K |
| 86900 |
|
6,062 |
5,148 |
$11K |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
270 |
228 |
$11K |
| 76801 |
|
1,418 |
1,257 |
$10K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
192 |
66 |
$10K |
| 97162 |
|
557 |
444 |
$10K |
| 73502 |
|
908 |
772 |
$10K |
| 86901 |
|
6,061 |
5,148 |
$9K |
| 36561 |
|
18 |
12 |
$9K |
| 83880 |
|
6,034 |
4,867 |
$9K |
| 70491 |
|
92 |
83 |
$8K |
| 87040 |
|
6,185 |
4,757 |
$8K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
1,164 |
1,076 |
$8K |
| 80061 |
Lipid panel |
1,767 |
1,470 |
$8K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,878 |
3,071 |
$8K |
| 83735 |
|
11,162 |
8,411 |
$8K |
| 12002 |
|
143 |
127 |
$8K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
64 |
51 |
$8K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,787 |
1,281 |
$7K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
82 |
82 |
$7K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
8,797 |
5,536 |
$6K |
| 87210 |
|
368 |
339 |
$6K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
3,759 |
2,036 |
$6K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
11,376 |
9,259 |
$5K |
| 87205 |
|
1,335 |
859 |
$5K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
11,754 |
9,115 |
$5K |
| J3490 |
Unclassified drugs |
1,381 |
874 |
$5K |
| 73590 |
|
296 |
248 |
$5K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
5,057 |
3,783 |
$5K |
| J1815 |
Injection, insulin, per 5 units |
5,597 |
2,336 |
$4K |
| 83605 |
|
5,941 |
4,541 |
$4K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
41 |
37 |
$4K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
8,344 |
6,173 |
$4K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,875 |
1,476 |
$4K |
| J2060 |
Injection, lorazepam, 2 mg |
4,701 |
3,196 |
$4K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
1,702 |
1,020 |
$4K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
211 |
194 |
$3K |
| 72040 |
|
94 |
83 |
$3K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
995 |
950 |
$3K |
| 80320 |
|
2,041 |
1,603 |
$3K |
| 85378 |
|
2,554 |
2,270 |
$2K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,984 |
2,456 |
$2K |
| 87430 |
|
5,072 |
4,824 |
$2K |
| 82040 |
|
945 |
823 |
$2K |
| 84460 |
|
938 |
814 |
$2K |
| 84155 |
|
948 |
818 |
$2K |
| 82247 |
|
937 |
814 |
$2K |
| 84450 |
|
933 |
810 |
$2K |
| 84075 |
|
935 |
813 |
$2K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
3,782 |
3,199 |
$2K |
| 73090 |
|
91 |
77 |
$2K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
362 |
278 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
1,768 |
1,499 |
$2K |
| 87276 |
|
11,545 |
10,686 |
$2K |
| 80329 |
|
1,324 |
1,004 |
$2K |
| 99152 |
|
158 |
130 |
$2K |
| 90714 |
|
1,404 |
1,213 |
$2K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
3,080 |
2,721 |
$1K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
915 |
798 |
$1K |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
67 |
50 |
$1K |
| 87075 |
|
190 |
142 |
$1K |
| 88342 |
|
1,054 |
906 |
$1K |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
1,790 |
1,393 |
$1K |
| 87400 |
|
4,665 |
4,342 |
$1K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
42 |
38 |
$1K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
2,306 |
1,773 |
$1K |
| 84100 |
|
3,751 |
2,834 |
$976.14 |
| 76642 |
|
12 |
12 |
$889.11 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
962 |
649 |
$822.10 |
| 87186 |
|
291 |
226 |
$685.99 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
994 |
949 |
$659.56 |
| 29125 |
|
133 |
124 |
$616.13 |
| 72110 |
|
99 |
82 |
$588.91 |
| C9113 |
Injection, pantoprazole sodium, per vial |
654 |
410 |
$582.58 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
1,855 |
1,225 |
$563.97 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
51 |
39 |
$561.65 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
16 |
12 |
$561.65 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
964 |
802 |
$556.67 |
| 96376 |
|
1,459 |
1,197 |
$539.33 |
| 72170 |
|
18 |
13 |
$496.13 |
| 78582 |
|
19 |
14 |
$491.70 |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
528 |
283 |
$451.21 |
| 99153 |
Mod sedat endo service >5yrs |
42 |
36 |
$439.11 |
| 74019 |
|
76 |
64 |
$421.14 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,301 |
1,241 |
$420.11 |
| 80143 |
|
664 |
536 |
$393.81 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
767 |
582 |
$338.97 |
| 36600 |
|
261 |
194 |
$329.11 |
| 87807 |
|
2,161 |
2,050 |
$324.96 |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
35 |
28 |
$318.88 |
| J3486 |
Injection, ziprasidone mesylate, 10 mg |
434 |
275 |
$292.59 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
864 |
762 |
$292.12 |
| 82248 |
|
3,642 |
2,488 |
$248.97 |
| 86140 |
|
1,568 |
1,398 |
$218.55 |
| 85651 |
|
1,103 |
974 |
$217.88 |
| 82009 |
|
1,139 |
949 |
$217.33 |
| J1630 |
Injection, haloperidol, up to 5 mg |
1,388 |
1,039 |
$183.64 |
| 82805 |
|
18 |
12 |
$182.91 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
759 |
436 |
$176.07 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
103 |
67 |
$167.39 |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
32 |
25 |
$166.43 |
| 85379 |
|
328 |
279 |
$161.32 |
| A6257 |
Transparent film, sterile, 16 sq. in. or less, each dressing |
20 |
16 |
$160.55 |
| 83540 |
|
254 |
209 |
$138.67 |
| 83615 |
|
401 |
323 |
$119.21 |
| 97116 |
|
412 |
191 |
$103.96 |
| 84132 |
|
206 |
162 |
$103.84 |
| 85007 |
|
174 |
155 |
$97.57 |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
33 |
25 |
$72.48 |
| G1003 |
Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program |
675 |
446 |
$60.92 |
| J0692 |
Injection, cefepime hydrochloride, 500 mg |
709 |
467 |
$50.76 |
| 88304 |
|
437 |
381 |
$35.60 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
19 |
13 |
$33.11 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
19 |
13 |
$33.11 |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
19 |
15 |
$31.37 |
| 82728 |
|
272 |
221 |
$21.50 |
| S5000 |
Prescription drug, generic |
1,487 |
692 |
$14.10 |
| 82140 |
|
23 |
15 |
$7.84 |
| 83550 |
|
192 |
160 |
$6.88 |
| 85018 |
|
91 |
55 |
$3.96 |
| 82150 |
|
534 |
453 |
$2.94 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
1,000 |
678 |
$0.96 |
| 76937 |
|
32 |
15 |
$0.00 |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
155 |
12 |
$0.00 |
| 85044 |
|
131 |
93 |
$0.00 |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
23 |
12 |
$0.00 |
| 87420 |
|
358 |
356 |
$0.00 |
| 80164 |
|
17 |
12 |
$0.00 |
| 84439 |
|
41 |
36 |
$0.00 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
22 |
19 |
$0.00 |
| C1788 |
Port, indwelling (implantable) |
17 |
12 |
$0.00 |
| J1953 |
Injection, levetiracetam, 10 mg |
19 |
13 |
$0.00 |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
16 |
12 |
$0.00 |
| J1940 |
Injection, furosemide, up to 20 mg |
90 |
42 |
$0.00 |
| J0456 |
Injection, azithromycin, 500 mg |
181 |
142 |
$0.00 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
189 |
168 |
$0.00 |
| 70498 |
|
61 |
50 |
$0.00 |
| J7999 |
Compounded drug, not otherwise classified |
187 |
150 |
$0.00 |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
15 |
14 |
$0.00 |
| 77001 |
|
20 |
13 |
$0.00 |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
54 |
51 |
$0.00 |
| 01400 |
|
30 |
28 |
$0.00 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
14 |
12 |
$0.00 |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
92 |
50 |
$0.00 |
| 82803 |
|
35 |
25 |
$0.00 |
| 86920 |
|
16 |
13 |
$0.00 |
| A9540 |
Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries |
19 |
14 |
$0.00 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
21 |
12 |
$0.00 |
| 86706 |
|
27 |
12 |
$0.00 |
| 88300 |
|
30 |
25 |
$0.00 |
| 82607 |
|
12 |
12 |
$0.00 |